Trial · NCT03668730
Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
NCT03668730, Phase 2, Unknown, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma. Trials, record NCT03668730. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03668730
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
- NCT number
- NCT03668730
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 215 participants, actual
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Intensity-modulated radiation therapy, Paclitaxel liposome, Cisplatin, 5-Fluorouracil
- First posted
- 2018-09-13
- Last updated
- 2021-08-24
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS(progression free survival) | 2 years | Defined from date of registration to date of first documentation of progression and/or distant metastasis,or death due to any cause. The primary study population for this endpoint is patients who were confirmed post-induction CR /PR and EBV DNA=0 and subsequently received 60Gy radiation therapy. |
| Secondary | Overall Survival(OS) | 2 years | Defined from date of registration to date of first documentation of death from any cause or censored at the date of the last follow-up. |
| Secondary | Locoregional relapse-free survival(LRFS) | 2 years | Defined from date of registration to date of first documentation of locoregional relapse or until the date of the last follow-up visit. |
| Secondary | Distant metastasis-free survival(DMFS) | 2 years | Defined from date of registration to date of first documentation of distant metastases or until the date of the last follow-up visit. |
| Secondary | Overall response rate | 2 years | Tumour response rate was classified according to RECIST, version 1.1 |
| Secondary | Incidence of acute toxicity | 2 years | Numbers of patients of treatment-related adverse events as assessed by CTCAE v4.0. |
| Secondary | Incidence of late toxicity | 2 years | Numbers of patients of late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme. |
| Secondary | Change of ADC( apparent diffusion coefficient ) value of DWI(Diffusion-Weighted MRI) of patients predictive of failure | 2 years | The ADC value of each patient of Diffusion-Weighted MRI at pretreatment and after induction chemotherapy was calculated were evaluated independently on a work station. |
| Secondary | Change of QoL | 1 years | QoL scores were assessed for each scale by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30) before induction chemotherapy, before radiotherapy, at the end of radiotherapy, at 3 months after radiotherapy, at 6 months after radiotherapy and 12 months after radiotherapy. |
| Secondary | Change of EORTC quality of life questionnaire(QLQ) Head and Neck score | 1 years | QoL scores were assessed by using EORTC quality of life questionnaire(QLQ) Head and Neck. The QLQ-H\&N35 is composed of seven multi-item symptom scales (pain, swallowing, sensation, speech, eating from a social,perspective, social interactions, and sexuality) and 11 single-item symptom scales (teeth, opening mouth,dry mouth, sticky saliva, coughing, felt ill, pain medication use, nutritional supplementation, feeding tube requirement, weight loss, and weight gain). All of the scales and items ranged in score from 0 to 100. A high score for a functional or global QoL scale represents a relatively high/healthy level of functional or global QoL, whereas a high score for a symptom scale or item represents a high number of symptoms or problems. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37801967 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03668730
GET https://conductscience.org/api/trials/v1/NCT03668730/registered